|
Market Closed -
BME
11:35:06 2026-10-02 am EDT
|
After hours 03:59:58 pm | |||
| 57.40 EUR | +0.09% |
|
57.58 | +0.30% |
| Jul. 23 | Laboratorios Farmaceuticos Rovi, S.A., H1 2026 Earnings Call, Jul 23, 2026 | |
| Jul. 23 | Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
Share class: Laboratorios Farmaceuticos Rovi, S.A.
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 51,235,762 | 16,208,105 ( 31.63 %) | 92,764 ( 0.1811 %) | 31.63 % |
Major shareholders: Laboratorios Farmaceuticos Rovi, S.A.
| Name | Stocks | % | Valuation |
|---|---|---|---|
Norbel Inversiones SL
58.19
%
| 29,812,040 | 58.19 % | 2 099 M € |
Indumenta Pueri SL
10.01
%
| 5,126,303 | 10.01 % | 361 M € |
Santander Private Banking Gestion SA SGIIC
1.142
%
| 584,879 | 1.142 % | 41 M € |
Invesco Asset Management Ltd.
0.959
%
| 491,351 | 0.959 % | 35 M € |
BN & Partners Capital AG
0.9344
%
| 478,736 | 0.9344 % | 34 M € |
Shareholder Value Management AG
0.8543
%
| 437,725 | 0.8543 % | 31 M € |
Muza Gestion de Activos SGIIC SA
0.6968
%
| 356,992 | 0.6968 % | 25 M € |
Financière de l'Échiquier SA
0.5681
%
| 291,086 | 0.5681 % | 20 M € |
Bestinver Gestión SA SGIIC
0.5133
%
| 263,004 | 0.5133 % | 19 M € |
Bankinter Gestión de Activos SA SGIIC
0.4085
%
| 209,297 | 0.4085 % | 15 M € |
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
Breakdown by shareholder type
| Others | 68.2% |
| Institutional | 10.04% |
| Laboratorios Farmaceúticos Rovi SA | 0.18% |
| Unknown | 21.58% |
Based on 1000 largest holdings
Geographical origin of shareholders
Spain | 73.91% |
Germany | 1.98% |
United Kingdom | 1.06% |
France | 0.77% |
Netherlands | 0.22% |
Italy | 0.16% |
Finland | 0.16% |
Luxembourg | 0.12% |
United States | 0.01% |
Belgium | 0.01% |
Malta | 0.01% |
Switzerland | 0.01% |
Based on 1000 largest holdings
Employees
2,470
Sector
Pharmaceuticals
Calendar
Nov. 05
Earnings release - Q3 2026
Select your edition
All financial news and data tailored to specific country editions
















